Skip to main content
Top
Published in: Journal of Neuro-Oncology 2/2019

Open Access 01-01-2019 | Clinical Study

The consistency of neuropathological diagnoses in patients undergoing surgery for suspected recurrence of glioblastoma

Authors: Matthias Holdhoff, Xiaobu Ye, Anna F. Piotrowski, Roy E. Strowd, Shannon Seopaul, Yao Lu, Norman J. Barker, Ananyaa Sivakumar, Fausto J. Rodriguez, Stuart A. Grossman, Peter C. Burger

Published in: Journal of Neuro-Oncology | Issue 2/2019

Login to get access

Abstract

Purpose

Clinical factors and neuro-imaging in patients with glioblastoma who appear to progress following standard chemoradiation are unable to reliably distinguish tumor progression from pseudo-progression. As a result, surgery is commonly recommended to establish a final diagnosis. However, studies evaluating the pathologists’ agreement on pathologic diagnoses in this setting have not been previously evaluated.

Methods

A hypothetical clinical history coupled with images of histological sections from 13 patients with glioblastoma who underwent diagnostic surgery for suspected early recurrence were sent to 101 pathologists from 50 NCI-designated Cancer Centers. Pathologists were asked to provide a final diagnosis (active tumor, treatment effect, or unable to classify) and to report on percent active tumor, treatment effect, and degree of cellularity and degree of mitotic activity.

Results

Forty-eight pathologists (48%) from 30 centers responded. In three cases > 75% of pathologists diagnosed active tumor. In two cases > 75% diagnosed treatment effect. However, in the remaining eight cases the disparity in diagnoses was striking (maximum agreement on final diagnosis ranged from 36 to 68%). Overall, only marginal agreement was observed in the overall assessment of disease status [kappa score 0.228 (95% CI 0.22–0.24)].

Conclusions

Confidence in any clinical diagnostic assay requires that very similar results are obtained from identical specimens evaluated by sophisticated clinicians and institutions. The findings of this study illustrate that the diagnostic agreement between different cases of repeat resection for suspected recurrent glioblastoma can be variable. This raises concerns as pathological diagnoses are critical in directing standard and experimental care in this setting.
Appendix
Available only for authorised users
Literature
1.
go back to reference Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9(5):453–461CrossRefPubMed Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9(5):453–461CrossRefPubMed
2.
go back to reference Brandes AA, Franceschi E, Tosoni A et al (2009) Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer 115(15):3512–3518CrossRefPubMed Brandes AA, Franceschi E, Tosoni A et al (2009) Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer 115(15):3512–3518CrossRefPubMed
3.
go back to reference de Wit MC, de Bruin HG, Eijkenboom W, Sillevis Smitt PA, van den Bent MJ (2004) Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 63(3):535–537CrossRefPubMed de Wit MC, de Bruin HG, Eijkenboom W, Sillevis Smitt PA, van den Bent MJ (2004) Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 63(3):535–537CrossRefPubMed
4.
go back to reference Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963–1972CrossRefPubMed Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963–1972CrossRefPubMed
5.
go back to reference Brandes AA, Franceschi E, Tosoni A et al (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26(13):2192–2197CrossRefPubMed Brandes AA, Franceschi E, Tosoni A et al (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26(13):2192–2197CrossRefPubMed
7.
go back to reference Chamberlain MC, Glantz MJ, Chalmers L, Van Horn A, Sloan AE (2007) Early necrosis following concurrent temodar and radiotherapy in patients with glioblastoma. J Neurooncol 82(1):81–83CrossRefPubMed Chamberlain MC, Glantz MJ, Chalmers L, Van Horn A, Sloan AE (2007) Early necrosis following concurrent temodar and radiotherapy in patients with glioblastoma. J Neurooncol 82(1):81–83CrossRefPubMed
8.
go back to reference Woodworth GF, Garzon-Muvdi T, Ye X, Blakeley JO, Weingart JD, Burger PC (2013) Histopathological correlates with survival in reoperated glioblastomas. J Neurooncol 113(3):485–493CrossRefPubMedPubMedCentral Woodworth GF, Garzon-Muvdi T, Ye X, Blakeley JO, Weingart JD, Burger PC (2013) Histopathological correlates with survival in reoperated glioblastomas. J Neurooncol 113(3):485–493CrossRefPubMedPubMedCentral
9.
go back to reference Galante JR, Rodriguez F, Grossman SA, Strowd RE (2017) Late post-treatment radiographic changes 3 years following chemoradiation for glioma: the importance of histopathology. CNS Oncol 6:195–201CrossRefPubMedCentral Galante JR, Rodriguez F, Grossman SA, Strowd RE (2017) Late post-treatment radiographic changes 3 years following chemoradiation for glioma: the importance of histopathology. CNS Oncol 6:195–201CrossRefPubMedCentral
10.
go back to reference Forsyth PA, Kelly FRCPC PJ, et al (1995) Radiation necrosis or glioma recurrence: is computer-assisted stereotactic biopsy useful? J Neurosurg 82(3):436–444CrossRefPubMed Forsyth PA, Kelly FRCPC PJ, et al (1995) Radiation necrosis or glioma recurrence: is computer-assisted stereotactic biopsy useful? J Neurosurg 82(3):436–444CrossRefPubMed
11.
go back to reference Kim J, Kim YB, Han JH et al (2012) Pathologic diagnosis of recurrent glioblastoma: morphologic, immunohistochemical, and molecular analysis of 20 paired cases. Am J Surg Pathol 36(4):620–628CrossRefPubMed Kim J, Kim YB, Han JH et al (2012) Pathologic diagnosis of recurrent glioblastoma: morphologic, immunohistochemical, and molecular analysis of 20 paired cases. Am J Surg Pathol 36(4):620–628CrossRefPubMed
12.
go back to reference Tihan T, Barletta J, Parney I, Lamborn K, Sneed PK, Chang S (2006) Prognostic value of detecting recurrent glioblastoma multiforme in surgical specimens from patients after radiotherapy: should pathology evaluation alter treatment decisions? Hum Pathol 37(3):272–282CrossRefPubMed Tihan T, Barletta J, Parney I, Lamborn K, Sneed PK, Chang S (2006) Prognostic value of detecting recurrent glioblastoma multiforme in surgical specimens from patients after radiotherapy: should pathology evaluation alter treatment decisions? Hum Pathol 37(3):272–282CrossRefPubMed
13.
go back to reference Fleiss JL (1971) Measuring nominal scale agreement among many raters. Psychol Bull 76(5):378–382CrossRef Fleiss JL (1971) Measuring nominal scale agreement among many raters. Psychol Bull 76(5):378–382CrossRef
15.
go back to reference Rosner N (1990) Fundamentals of biostatistics. PWS-KENT Publishing Company, Boston Rosner N (1990) Fundamentals of biostatistics. PWS-KENT Publishing Company, Boston
17.
go back to reference Wolff AC, Hammond ME, Schwartz JN et al (2007) American society of clinical Oncology/College of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25(1):118–145CrossRefPubMed Wolff AC, Hammond ME, Schwartz JN et al (2007) American society of clinical Oncology/College of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25(1):118–145CrossRefPubMed
18.
go back to reference Allsbrook WC Jr, Mangold KA, Johnson MH et al (2001) Interobserver reproducibility of gleason grading of prostatic carcinoma: Urologic pathologists. Hum Pathol 32(1):74–80CrossRefPubMed Allsbrook WC Jr, Mangold KA, Johnson MH et al (2001) Interobserver reproducibility of gleason grading of prostatic carcinoma: Urologic pathologists. Hum Pathol 32(1):74–80CrossRefPubMed
Metadata
Title
The consistency of neuropathological diagnoses in patients undergoing surgery for suspected recurrence of glioblastoma
Authors
Matthias Holdhoff
Xiaobu Ye
Anna F. Piotrowski
Roy E. Strowd
Shannon Seopaul
Yao Lu
Norman J. Barker
Ananyaa Sivakumar
Fausto J. Rodriguez
Stuart A. Grossman
Peter C. Burger
Publication date
01-01-2019
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 2/2019
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-018-03037-3

Other articles of this Issue 2/2019

Journal of Neuro-Oncology 2/2019 Go to the issue